Fig. 3

PVRIG deficiency slows tumor growth and prevents exhaustion of tumor-infiltrating NK cells in various solid tumor models. a, b WT (n = 10) and PVRIG KO (n = 9) mice were subcutaneously injected with 2 × 10⁵ MC38 cells, and the tumor size was measured every two days. a Median tumor size and b mouse survival over time were shown. c Representative photograph and d weight of tumor as in a (n = 8 per group) on day 25 after challenge. e Percentage of CD107a⁺, Granzyme B (GzmB)⁺ or IFN-γ⁺ tumor-infiltrating NK cells in WT and PVRIG KO mice (n = 7 or 8 per group). f Percentage of Ki67⁺ tumor-infiltrating NK cells in WT and PVRIG KO mice (n = 7 per group). g, h WT (n = 10) and PVRIG KO (n = 10) mice were subcutaneously injected with 1 × 10⁶ LLC cells and the tumor size was measured every two days. g Median tumor size and h mouse survival over time were shown. i, j WT (n = 11) and PVRIG KO (n = 13) mice were subcutaneously injected with 5 × 10⁴ MCA205 cells and the tumor size was measured every 2 days. i Median tumor size and j mouse survival over time were shown. Each symbol represents an individual mouse. Data were representative of at least two independent experiments. Error bars represent means ± s.e.m. Statistical significance was determined using two-way ANNOVA (a, g, i), Mantel–Cox test (b, h, j) or unpaired two-tailed t test (d–f). *p < 0.05; **p < 0.01; ***p < 0.001 and ****p < 0.0001